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Abstract
Objective To determine the effect of mammography screening on
surgical treatment for breast cancer.
Design Comparative analysis of data from Norwegian cancer registry.
Setting Mammography screening, Norway (screening of women aged
50-69 was introduced sequentially from 1996 to 2004).
Participants 35 408 women aged 40-79 with invasive breast cancer or
ductal carcinoma in situ treated surgically from 1993 to 2008.
Main outcome measures Rates of breast surgery (mastectomy plus
breast conserving treatment) and rates of mastectomy for three age
groups of women: 40-49, 50-69, and 70-79. Changes in rates from
pre-screening period (1993-5) to introduction of screening phase
(1996-2004) and then to screening period (2005-8) are presented as
hazard ratios in invited and non-invited women.
Results The annual rate for breast surgery from the pre-screening period
(1993-5) to screening period (2005-8) in Norway increased by 70%
(hazard ratio 1.70, 95% confidence interval 1.62 to 1.78), from 180 to
305 per 100 000 women in the invited age group (50-69 years). In the
younger, non-invited age group (40-49 years), however, the increase
was only 8% (1.08, 1.00 to 1.16), from 133 to 144 per 100 000 women
per year, whereas in the older, non-invited age group (70-79 years) the
rate decreased by 8% (0.92, 0.86 to 1.00), from 227 to 214 per 100 000
women per year. The rates for mastectomy decreased similarly from the
pre-screening period to screening period in invited and non-invited
women. From the pre-screening period to the introduction phase of
screening (1996-2004), however, the annual mastectomy rate in women
aged 50-69 invited to screening increased by 9% (1.09, 1.03 to 1.14),
from 156 to 167 per 100 000 women, and in the younger non-invited
women declined by 17% (0.83, 0.78 to 0.90), from 109 to 91 per 100
000 women. In consequence, the mastectomy rate was 31% (1.31, 1.20
to 1.43) higher in the invited than in the non-invited younger age group.
Conclusions Mammography screening in Norway was associated with
a noticeable increase in rates for breast cancer surgery in women aged
50-69 (the age group invited to screening) and also an increase in
mastectomy rates. Although over-diagnosis is likely to have caused the
initial increase in mastectomy rates and the overall increase in surgery
rates in the age group screened, the more recent decline in mastectomy
rates has affected all age groups and is likely to have resulted from
changes in surgical policy.
Introduction
The objective of mammography screening is to improve the
timing of breast cancer diagnosis, thereby reducing the number
of associated deaths. A potential additional benefit often stated
in invitations to screening and on websites supported by
governmental screening institutions is that screening reduces
the need for mastectomies and increases the potential for breast
conserving treatment.
1-3 In contrast, a Cochrane review of
randomised trials on mammography reported a 31% increase
inbreastsurgery(mastectomyplusbreastconservingtreatment)
and 20% more mastectomies in women exposed to screening
than in the control group.
4
In the Norwegian breast cancer screening programme, women
aged 50-69 are invited to biennial screening. The programme
startedin1996inthefourcountiesofAkershus,Oslo,Rogaland,
andHordalandandincluded40%oftheNorwegianpopulation.
From1999to2004theremaining15countiesweresuccessively
included.
5
We used Norwegian population based data for the period 1993
to 2008 to assess how the stepwise introduction of
mammography screening has affected surgical treatment for
breast cancer—that is, the number of women undergoing
mastectomyorbreastsurgery(mastectomyorbreastconserving
treatment)forinvasivebreastcancerorductalcarcinomainsitu.
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Research
RESEARCHWe also determined how surgical treatment by disease stage at
diagnosis has changed during the period.
Methods
FromtheNorwegiancancerregistryweobtainedaggregatedata
on incidence and surgical treatment of women aged 40-79 with
ductalcarcinomainsituorinvasivebreastcancer.Thedatawere
stratified by stage and included the period 1993-2008. The
cancer registry collects information on stage of disease at the
time of diagnosis; stage 0 (ductal carcinoma in situ), stage I
(invasive breast cancers of diameter ≤2.0 cm and no lymph
nodeinvolvementordistantmetastasis),stageII(invasivebreast
cancers of diameter ≤5.0 cm and 1-3 positive lymph nodes but
no distant metastasis, or invasive breast cancers of diameter
>2.0 cm with no positive lymph nodes or distant metastasis),
andstageIIIandIV(tumoursofdiameter>5cmand1-3positive
lymph nodes, any tumour with direct extension to chest wall or
skin, any tumour with >3 positive lymph nodes, or any tumour
with distant metastasis).
Basedonclinicalnotificationsandpathologyreportsthecancer
registry classifies each patient (identified by a unique personal
identification number) to have undergone either breast
conserving treatment or mastectomy or neither. If breast
conserving treatment is followed by mastectomy within four
months, the case is coded as a mastectomy. We requested data
on the treatment of primary cases—that is, the first episode of
breast cancer for each woman. Cases of invasive cancer are
counted whether or not the women have had ductal carcinoma
insitupreviously.Casesofductalcarcinomainsituarecounted
only when the lesions have no invasive component, the women
have not had invasive breast cancer previously, and the ductal
carcinoma in situ is not followed by invasive breast cancer
within four months.
Statistical analysis
We calculated age specific incidence rates, rates of breast
surgery (breast conserving treatment plus mastectomy), and
rates of mastectomy for invasive breast cancer and ductal
carcinoma in situ grouped together for three age groups of
women: 40-49, 50-69, and 70-79 years. Depending on the start
of mammography screening, we stratified women aged 50-69
into two geographical subgroups (those from the counties of
Akershus, Oslo, Rogaland, and Hordaland and those from the
remaining 15 Norwegian counties) and calculated age specific
mastectomy rates. To determine how the introduction of
screeningaffectedbreastcancersurgerybystage,wecalculated
age specific mastectomy and breast surgery rates for stages 0,
I, II, and III/IV for women aged 50-69 years.
Based on the national availability of mammography screening,
we divided the study period into pre-screening (1993-5),
introduction of screening phase (1996-2004), and screening
(2005-8). To compare changes in use of breast cancer surgery
between periods with and without screening, we estimated
changes in mastectomy and breast surgery rates in the three age
groupsfrompre-screeningtotheintroductionofscreeningphase
and from pre-screening to screening. We used a Poisson
regression model adjusting for age only. Changes in rates of
surgery over time are presented as hazard ratios.
To determine changes in use of breast cancer surgery between
screenedandnon-screenedagegroups,weusedaPoissonmodel
to compare the changes in mastectomy and breast surgery rates
in women aged 50-69 versus women aged 40-49, adjusting for
changes in age distribution and for an underlying linear trend.
Finally, we divided the data into two geographical subgroups,
taking advantage of regional variations in the start of screening
in Akershus, Oslo, Rogaland, and Hordaland counties and the
remaining15counties.Wecomparedmastectomyratesbetween
women aged 50-69 and 40-49 in two periods; pre-screening
(1993-5inAkershus,Oslo,Rogaland,andHordalandand1993-8
in the other counties) and introduction of screening (1996-7 in
Akershus, Oslo, Rogaland, and Hordaland and 1999-2004 in
the other counties). In this analysis we used a Poisson model,
adjusting for changes in age distribution and an underlying
linear trend.
Results
In2008theNorwegianpopulationincludedonemillionwomen
aged 40-79. In the study period from 1993-2007 the cancer
registry recorded 32 200 cases of invasive breast cancer and
3208 cases of ductal carcinoma in situ in this age group. Data
on surgical treatment were available for 94% of the invasive
cancercasesand98%oftheductalcarcinomainsitucases(table
1⇓).Figure1⇓presentstheagespecificincidenceratesandrates
of breast surgery and mastectomy for ductal carcinoma in situ
and invasive breast cancer for the age groups 40-49, 50-69, and
70-79combined.From1996to2002mastectomyratesdecreased
gradually in the 40-49 and 70-79 age groups but temporarily
increasedinthe50-69agegroup.Theincreasewasevidentonly
in Akershus, Oslo, Rogaland, and Hordaland where prevalence
screening was carried out in 1996-7 (fig 2⇓). In the remaining
counties where screening started later, mastectomy rates were
stable from 1996-2002 (fig 2). From 2002-3 mastectomy rates
declined in all counties.
Figure3⇓showsthenationalratesforsurgerystratifiedbystage
of disease for women aged 50-69. Rates of breast surgery for
stages 0, I, and II all increased during the study period.
Mastectomy rates for stage I noticeably increased temporarily
in the first three years when screening was introduced, and
decreased after 2002. The mastectomy rates for stage 0 and
stage II increased from 1996 but decreased from about 2003.
Rates of mastectomies and breast surgery for stage III and IV
tumours did not change noticeably.
Table 2⇓ shows the annual rates of mastectomy and breast
surgeryforallstagesofinvasivecancerandforductalcarcinoma
in situ in the three periods. The estimated hazard ratios
comparing the pre-screening period with the screening
introduction phase and the pre-screening period with screening
period are also presented. During the screening introduction
phase,mastectomyratesincreasedby9%inthe50-69agegroup
but decreased by 17% in the 40-49 age group and by 13% in
the 70-79 age group. Using Poisson regression to compare the
1.09 relative change (invited women aged 50-69) with the
expected 0.83 relative change (assuming a similar reduction
between age groups 50-69 and 40-49) the relative risk of
mastectomy in the 50-69 age group increases by 31% (hazard
ratio 1.31, 95% confidence interval 1.20 to 1.43).
From the pre-screening period to screening period the
mastectomy rates decreased by 30% in the 50-69 age group,
35% in the 40-49 age group, and 41% in the 70-79 age group
(table 2). Using a Poisson model the decrease in mastectomy
rates did not differ significantly between the 50-69 and 40-49
age groups (1.08, 0.97 to 1.21). The total number of breast
operationsfromthepre-screeningtoscreeningperiodincreased
by 70% in the 50-69 age group compared with 8% in the 40-49
age group and decreased by 8% in the 70-79 age group.
In contrast with Akershus, Oslo, Rogaland, and Hordaland, the
mastectomy rate in the remaining counties did not increase in
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RESEARCHthe screening introduction phase (fig 2). Women aged 50-69
werestratifiedinAkershus,Oslo,Rogaland,andHordalandand
the remaining counties and the hazard ratio for mastectomy
compared between the pre-screening period and the screening
introduction phase. During the screening introduction phase in
Akershus,Oslo,Rogaland,andHordaland(1996-7)mastectomy
rates increased by 48% (1.48, 1.23 to 1.78) in the 50-69 age
group relative to the rates in the 40-49 age group. In the
remaining counties, screening was introduced later and more
gradually.Duringtheintroductionofscreeninginthesecounties
(1999-2004) mastectomy rates increased by 21% (1.21, 1.09 to
1.34) in the 50-69 age group relative to the rates in the 40-49
age group.
Discussion
A potential benefit of mammography screening—a reduction
in mastectomy rates and an increase the use of less invasive
surgery—was not corroborated by our results, which show that
mastectomy rates in Norway have declined similarly in invited
and non-invited age groups from the pre-screening period
(1993-5) to the more recent screening period (2005-8). During
the introduction of screening, mastectomy rates in invited
women aged 50-69 increased by 9%. In contrast, during the
same period the rates in non-invited women decreased by 17%
inthe40-49agegroupandby13%inthe70-79agegroup.This
correspondstoa31%increaseintherelativeriskofmastectomy
in women invited to screening compared with the non-invited
younger age group. Mastectomy rates noticeably increased in
Akershus, Oslo, Rogaland, and Hordaland counties when
screening started in 1996. Since the detection rate is higher
during prevalence screening than in the subsequent screening
rounds,moremastectomieswouldbeexpectedintheprevalence
screeninground.Intheremaining15Norwegiancountieswhere
screeningwasintroducedlaterandmoregraduallyin1999-2004,
the absolute number of mastectomies did not increase during
thescreeningintroductionphase;althoughinrelativeterms,the
increase was 21% compared with the younger non-invited age
group. The more modest change in mastectomy rates in the 15
countiesinthescreeningintroductionphase(smallerprevalence
peak than in Akershus, Oslo, Rogaland, and Hordaland) can be
explained by the more gradual introduction of the screening
programme and the non-organised private screening activity
before the screening programme started. In addition, during the
observationperiodchangesinsurgicalpracticeinNorwayhave
reduced mastectomy rates in all age groups. As part of the
mammography screening programme, specialist breast clinics
with a focus on multidisciplinary teamwork between
radiologists, pathologists, and surgeons were established. As a
consequence, the numbers of Norwegian hospitals carrying out
breast cancer surgery have declined, from around 60 to 20.
6 It
is likely that this has influenced the treatment of non-screened
age groups as a spin-off effect.
Themastectomyratesforstages0,I,andIIincreasedinwomen
aged50-69inthefirstyearsofthescreeningintroductionphase.
Rates decreased for all stages except III and IV from 2002-3,
reflecting that changes in surgical practice affect both lymph
node positive and negative invasive cancers with a diameter
less than 5 cm, as well as ductal carcinoma in situ. Rates of
breast surgery have increased especially for stages 0 and I, but
also for stage II.
The risk of surgery for invasive breast cancer or ductal
carcinoma in situ increased by 70% in the 50-69 age group in
the screening period compared with pre-screening period. In
contrast, the risk increased by 8% in non-invited women in the
40-49 age group. The introduction of the Norwegian
mammography screening programme was associated with a
more than 50% increase in the incidence of invasive breast
cancer in women aged 50-69.
7 In addition many cases of ductal
carcinoma in situ are detected by screening, and ductal
carcinoma in situ now constitutes 13% of breast cancer
diagnoses in Norway in the screened age group. A recent
systematic review of five screening programmes estimated that
screening is associated with a 52% over-diagnosis of breast
cancer,includingcasesofductalcarcinomainsitu,whichwould
not have been identified clinically in the women’s remaining
lifetimes.
8
Strengths and limitations of the study
We used population based data from the Norwegian cancer
registry, which contains virtually all cancers diagnosed in
Norway, with only 0.5% of the cases lacking information on
stage.
9 The information on type of surgical treatment is also
nearly complete, with only 5% of cases lacking a surgery code,
either because of missing data or because the patient did not
have surgery.
The rates of attendance in the Norwegian mammography
screening programme are high and stable; 75-77% in 2002-6.
5
In Norway the rates for ductal carcinoma in situ increased from
9 to 40 per 100 000 women aged 50-69 from 1993 to 2008. In
contrast the rates for ductal carcinoma in situ for women aged
40-49and70-79havebeenessentiallyconstant,indicatinglittle
screening activity outside the invited age group.
This study also has limitations. In addition to the stage and size
of tumours, surgical treatment is influenced by several other
patient,surgeon,andhospitalfactors.
10Sinceweusedaggregated
data,ouroptionstoadjustforfactorsotherthantheintroduction
of screening were limited. Geographical differences may have
influenced the type of surgery chosen because of variation in
surgical tradition and skills and because of the long travelling
distancestoradiationtherapyunitsfromsomepartsofNorway.
By using the age group 40-49 as a control group, we limited
potentialbiasfromgeographicaldifferencesbecausescreenand
non-screendetectedcancersfromanareaaretreatedatthesame
breast clinics, and women aged 40-49 are generally expected
to be offered the same treatment as women aged 50-69. Some
cancers that currently are detected by screening in women aged
50-69 would in the absence of screening have been diagnosed
afterage69years.Thisisexpectedtoresultinreducedincidence
and surgery rates for women aged 70-79. But the decline in
incidence and breast surgery rates in women aged 70-79 was
small and can only compensate for a fraction of the increase in
incidence and breast surgery rates in women invited to
screening.
7 8
In a recent review, preoperative magnetic resonance imaging
was associated with more radical surgery.
11 Increased access to
modern breast reconstruction after mastectomy may have a
similar effect. In Norway, however, the use of preoperative
magnetic resonance imaging and breast reconstruction after
mastectomywerelimitedduringthestudyperiod.IntheUnited
Statesanincreaseintheproportionofbreastcancercasestreated
by mastectomy has been reported in recent years,
12 mainly
explained by changes in patients’ attitudes and choices. Until
2008 this trend was not seen in data from Norway.
Comparison with other studies
Published data on how the introduction of mammography
screening affects the type of surgery are limited. Similar trends
inmastectomyrateswerefoundinastudythatcomparedsurgery
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RESEARCHduring 1994-9 in Northern Ireland (with screening) with that in
theRepublicofIreland(withoutscreening).
13StudiesfromItaly
have shown declining mastectomy rates in the screening
period,
14 15 but control groups have been missing. A study from
the United Kingdom reported increased mastectomy rates for
ductal carcinoma in situ within the screening programme but
didnotreportdataforinvasivebreastcancer.
16Recentdatafrom
Denmarkshowalargeincreaseinmastectomieswhenscreening
first started that was not compensated for later on.
17
Conclusions
Mammographyscreeningisassociatedwithanoticeableincrease
in breast surgery rates. In contrast with what has been claimed
in invitations to screening and on websites supported by
numerous governmental screening institutions and cancer
charities, screening does not lead to a reduction in mastectomy
rates. When screening was introduced in Norway, mastectomy
ratesincreased.Inrecentyears,asaresultofchangestosurgical
policy, mastectomy rates have declined for all age groups, but
mostly for the non-screened age groups.
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RESEARCHWhat is already known on this topic
Mammography screening increases overall rates of breast surgery
Women invited to mammography screening are informed that participation reduces their risk of having a mastectomy
What this study adds
Mammography screening is associated with an increase in mastectomy rates, especially when screening is in its
introduction phase
Women should be informed that higher overall breast surgery rates in those invited to mammography screening partly
results from higher mastectomy rates
Tables
Table 1| Number of cases and surgical treatment of invasive breast cancer and ductal carcinoma in situ in Norwegian women aged 40-79,
1993 to 2008
Population of
women aged
40-79
Missing information
Treatment for ductal carcinoma
in situ
Treatment for invasive breast
cancer
Ductal
carcinoma
in situ
Invasive
breast
cancer Year
Ductal
carcinoma
in situ
Invasive
breast cancer
Breast
conserving
therapy Mastectomy
Breast
conserving
therapy Mastectomy
882 064 0 122 23 53 171 1228 76 1521 1993
889 565 0 100 20 66 174 1307 86 1581 1994
897 142 0 127 32 55 197 1322 87 1646 1995
904 611 0 113 61 100 280 1498 161 1891 1996
912 580 3 103 82 118 328 1525 203 1956 1997
919 467 0 124 83 114 488 1331 197 1943 1998
927 020 1 116 70 90 511 1318 161 1945 1999
936 320 2 109 91 112 650 1278 205 2037 2000
941 338 2 83 101 106 782 1286 209 2151 2001
947 989 3 82 124 116 937 1167 243 2186 2002
955 825 5 88 150 82 1198 945 237 2231 2003
964 939 1 98 195 86 1244 899 282 2241 2004
976 041 3 110 188 80 1284 847 271 2241 2005
988 656 7 98 166 76 1200 875 249 2173 2006
1 002 024 14 108 176 83 1155 933 273 2196 2007
1 017 298 14 208 150 104 1147 906 268 2261 2008
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RESEARCHTable 2| Rates of breast surgery and mastectomies and changes in rates of both invasive breast cancer and ductal carcinoma in situ for
women aged 40-49, 50-69, and 70-79 in Norway in relation to screening periods
Hazard ratio (95% CI) Rate per 100 000 women per year Outcome by age group
2005-8 v 1993-5 1996-2004 v 1993-5 Screening (2005-8) Introduction of screening
(1996-2004)
Pre-screening (1993-5)
Breast surgery:
1.08 (1.00 to 1.16) 1.07 (1.00 to 1.14) 144.1 140.7 132.5 40-49
1.70 (1.62 to 1.78) 1.67 (1.60 to 1.75) 305.1 298.1 179.7 50-69*
0.92 (0.86 to 1.00) 0.99 (0.93 to 1.06) 213.6 225.4 226.9 70-79
Mastectomy:
0.65 (0.59 to 0.71) 0.83 (0.78 to 0.90) 71.4 90.9 109.5 40-49
0.70 (0.66 to 0.75) 1.09 (1.03 to 1.14) 106.3 166.9 155.7 50-69*
0.59 (0.54 to 0.64) 0.87 (0.82 to 0.94) 122.2 180.9 205.6 70-79
*Invited age group in screening programme.
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RESEARCHFigures
Fig 1 Age specific mastectomy, breast surgery (mastectomy plus breast conserving treatment), and incidence rates in
Norwegian women with invasive breast cancer or ductal carcinoma in situ according to age group (women aged 50-69 are
invited to screening)
Fig 2 Mastectomy rates in Norwegian women aged 50-69 (age group invited to screening) with invasive breast cancer or
ductal carcinoma in situ in Akershus, Oslo, Rogaland, and Hordaland counties (screening started in 1996) and remaining
15 counties (screening started 1999-2004)
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RESEARCHFig 3 Age specific rates of breast surgery (mastectomy plus breast conserving treatment) and mastectomy in Norwegian
women aged 50-69 (age group invited to screening) stratified by stage
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